Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection

• Published in: Diabetes & metabolism journal Vol. 46; no. 6; pp. 827 - 828
• Main Author: Cho, Eun-Hee
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Diabetes Association / Daehan Dangnyobyeong Hakoe 01.11.2022; Korean Diabetes Association; 대한당뇨병학회
• Subjects: Agonists; Antidiabetics; Chronic illnesses; Clinical trials; Comorbidity; Conflicts of interest; Diabetes; Edema; Glucose; Hypoglycemia; Hypoglycemic Agents - therapeutic use; Insulin; Insulin resistance; Ischemia; Kidney diseases; Pathophysiology; Thiazolidinediones - therapeutic use; 내과학
• ISSN: 2233-6079; 2233-6087; 2233-6087
• DOI: 10.4093/dmj.2022.0372

The American Diabetes Association (ADA) 2022 guidelines [9] recommends that first-line therapy depends on comorbidities, patient-centered treatment factors and a GLP-1RA or a SGLT2 inhibitor is recommended as an appropriate initial therapy for individuals with T2DM with comorbidity such as atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and/or chronic kidney disease (CKD). The PROactive trial showed that pioglitazone decreased the ‘main secondary endpoint’ of all-cause mortality, non-fatal myocardial infarction, and stroke compared to placebo in 5,238 patients with T2DM with prior cardiovascular (CV) event, but there was no significant difference in the primary composite endpoint including additional acute coronary syndrome, endovascular or surgical intervention in the coronary or leg arteries, and amputation above the ankle [10]. NOTES CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was reported. 1.